AbbVie acquired Landos Biopharma, Inc., a transaction completed in June 2024.
Landos Biopharma, Inc. operates in Immunology (IBD), is based in Blacksburg, Virginia. AbbVie completed its acquisition of Landos Biopharma, adding the first-in-class investigational asset ABBV-113 (NX-13) to its pipeline. ABBV-113 offers a novel oral approach to treating ulcerative colitis (UC) and Crohn's disease (CD).
Adds a novel first-in-class oral immunology asset for inflammatory bowel disease to AbbVie's pipeline.
Advisory firms were not disclosed for this transaction.